US EditionPublished • loading... • Updated
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Summary by PR Newswire
20 Articles
20 Articles
NiagaraFallsReview.caReposted by 
The Toronto Star
The Toronto StarXORTX Announces Closing of US$1.1 Million Registered Direct Offering
CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease,…
·Niagara Falls, Canada
Read Full Article
Farm Talk Newspaper+16 Reposted by 16 other sources
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
$3.4 million upfront with up to an additional $6.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
·Parsons, United States
Read Full Article
Coverage Details
Total News Sources20
Leaning Left2Leaning Right0Center10Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
